The order eases restrictions on psychedelic drugs like ibogaine to spur research on using the them for medical purposes.

The executive order will open the door for more research into the psychedelic drug ibogaine, sources told CBS News earlier ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...

Under the new priority voucher program (CNPV), the FDA has approved a new oral GLP-1 drug, Foundayo, offering an alternative ...

It’s been a little over two months since President Donald Trump’s direct-to-consumer pharmaceutical site, TrumpRx, launched, ...

WILMINGTON, DE — AstraZeneca (NYSE: AZN) said its experimental drug tozorakimab reduced moderate-to-severe exacerbations in ...

AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race. Strong trial data boosts AstraZeneca’s long-term revenue outlook. Shares of ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An AstraZeneca sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 6, 2020.

March 27 (Reuters) – AstraZeneca’s experimental drug tozorakimab reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, sending its shares up as much as 3.8% on Friday on ...